Table 8 Summary of the main clinical studies evaluating sTREM-1 prognostic value
Gibot et al. 2005 [16] | Giamarellos-Bourboulis et al. 2006 [19] | Zhang et al. 2011 [23] | Jeong et al. 2012 [15] | Su et al. 2012 [24] | Li et al. 2014 [13] | Ravetti et al. 2015 [17] | Our study | |
|---|---|---|---|---|---|---|---|---|
Nb. of Patients | 63 | 90 | 52 | 63 | 130 (100 with sepsis) | 102 | 40 with cancer | 190 |
Median Age | 61 | Unknown | Unknown | 63.7 | 58.9 | 63 | 67 | 60.6 |
Unit | ICU | ICU | ICU | ER (and then ICU) | ICU | ICU | ICU | ICU |
Severity of sepsis | Septic shock (53 %) | Severe sepsis + Septic shock (70 %) | Severe sepsis + Septic shock (71.1 %) | Severe sepsis + Septic shock (100 %) | Severe sepsis + Septic shock (64 %) | Sepsis, Severe sepsis and Septic shock | Severe sepsis + Septic shock (100 %) | Septic shock (68.4 %) |
Site of Infection | Miscellaneous | VAP | Miscellaneous | Miscellaneous | Miscellaneous | Miscellaneous | Miscellaneous | Miscellaneous |
Overall Mortality | 33 % (ICU) | 36.7 % | 30.7 % (D28) | 25.4 % (D28) | 43 % (D28) | 41.2 % (D28) | In cancer patients: | 25.8 % (ICU) |
34.7 % (ICU) | ||||||||
40 % (D28) | ||||||||
SAPS II | 53 (21) | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | 52.6 (21.5) |
APACHE 2 | Unknown | Unknown | Unknown | Unknown | 13.4 (6.1) | Unknown | In cancer patients 19.9 (5.1) | Unknown |
SOFA D0 | 936 (3.1) | Unknown | Unknown | Unknown | 7.8 (4.4) | Unknown | 6.2 (2.7) | 9 (5.2) |
Type of sample | - sTREM1 | - Serum | - Serum | - Serum | - Serum | - Serum | - Serum | - Serum |
- sTREM1 | - sTREM1 | - sTREM1 | - sTREM1 | - sTREM1 | - sTREM1 | - sTREM1 | ||
- ELISA | - ELISA | - ELISA | - ELISA | - ELISA | - ELISA | - ELISA | ||
Median sTREM1 level on admission (pg/ml) | In Cancer Patients | |||||||
Survivors | 154 | Unknown | 193.4 | 182.4 | Unknown | 161.95 | 848 | 671 |
Non survivors | 94 (p = 0.02) | Unknown | 240.2 (NS) | 514.1 (p = 0.001) | Unknown | 320 (p < 0.001) | 558 (NS) | 1148 (p < 0.01) |
sTREM1 cut-off value (pg/ml) | 180 (baseline) | 252.05 (baseline) | 954.4 (baseline) | |||||
Sensitivity | 86 % | 85.7 % | 54.5 % | |||||
Specificity | 70 % | 75.7 % | 78 % | |||||
AUROCC | 0.74 | 0.856 | 0.64 | |||||
PPV | 70.6 % | 49.2 % | ||||||
NPV | 88.2 % | 81.5 % | ||||||
Best Relevant Prognostic Predictor (associated with sTREM1) | -sTREM1 baseline | - sTREM1/IL-6 baseline ratio | None (sTREM1 increase between D1 and D14 was NS) | - Log (sTREM1) baseline | None | sTREM1 (baseline > 252.05) | -sTREM1 value on D2 for ICU mortality. AUROCC = 0.69 | sTREM1 (baseline value > 954.4) + SAPS II (>67.5) |
Other relevant Predictors | - SOFA baseline | - TNF alpha baseline | - SOFA score baseline and evolution | - ScVO2 baseline | - sTREM1 value on D1 for D28 mortality. AUROCC = 0.75 | |||
- IL-6 baseline | - SAPS II | - SOFA | - PCT (baseline > 10.6 ng/ml) | - Days of MV | - SAPS II | |||
- IL-10/IL-6 baseline ratio | - sCD163 | - SOFA baseline > 6.5 | - Use of corticosteroids | - Core Temperature |